Targeted Treatment for Chronic Lymphocytic Leukemia

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2011 Dec 14

PMID 22162923

Citations 3

Authors

Aisha Masood

Taimur Sher

Aneel Paulus

Kena C Miller

Kasyapa S Chitta

Asher Chanan-Khan

Affiliations

Soon will be listed here.

Abstract

The treatment of chronic lymphocytic leukemia (CLL) has evolved over the last few decades. Recognition has increased of several key components of CLL biology currently manipulated for therapeutics. A milestone in the treatment of CLL was reached with the incorporation of immunotherapy with conventional chemotherapy. The fludarabine/cyclophosphamide/rituximab combination has demonstrated survival advantage for the first time in the treatment of CLL. Several other biological compounds are being explored with the hope of improving responses, impacting survival, and ultimately curing CLL. Important agents being tested are targeted on CLL surface molecules and their ligands, signal transduction protein and oncogenes. This review provides a brief summary of the recent advances made in preclinical and clinical investigation of selected promising therapeutic agents, which lead the target-directed therapeutic approach.

Citing Articles

Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer.

Ngoi N, Choong C, Lee J, Bellot G, Wong A, Goh B Cancers (Basel). 2020; 12(3).

PMID: 32131385 PMC: 7139457. DOI: 10.3390/cancers12030574.

Tumor-selective cytotoxicity of a novel pentadiene analogue on human leukemia/ lymphoma cells.

Santiago-Vazquez Y, Das U, Varela-Ramirez A, Baca S, Ayala-Marin Y, Lema C Clin Cancer Drugs. 2016; 3(2):138-146.

PMID: 27857884 PMC: 5110259. DOI: 10.2174/2212697X03666160830165250.

A novel class of piperidones exhibit potent, selective and pro-apoptotic anti-leukemia properties.

Nunes L, Hossain M, Varela-Ramirez A, Das U, Ayala-Marin Y, Dimmock J Oncol Lett. 2016; 11(6):3842-3848.

PMID: 27313705 PMC: 4888252. DOI: 10.3892/ol.2016.4480.

References

Lin K, Rockliffe N, Johnson G, Sherrington P, Pettitt A . Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene. 2007; 27(17):2445-55. DOI: 10.1038/sj.onc.1210893. View

Byrd J, Peterson B, Morrison V, Park K, Jacobson R, Hoke E . Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2002; 101(1):6-14. DOI: 10.1182/blood-2002-04-1258. View

Advani R, Forero-Torres A, Furman R, Rosenblatt J, Younes A, Ren H . Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2009; 27(26):4371-7. DOI: 10.1200/JCO.2008.21.3017. View

Hallek M, Cheson B, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-56. PMC: 2972576. DOI: 10.1182/blood-2007-06-093906. View

Chiorazzi N, Ferrarini M . Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood. 2010; 117(6):1781-91. PMC: 3056635. DOI: 10.1182/blood-2010-07-155663. View

Eichhorst B, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C . Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2005; 107(3):885-91. DOI: 10.1182/blood-2005-06-2395. View

Awan F, Lapalombella R, Trotta R, Butchar J, Yu B, Benson Jr D . CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood. 2009; 115(6):1204-13. PMC: 2826232. DOI: 10.1182/blood-2009-06-229039. View

Caligaris-Cappio F . Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol. 2003; 123(3):380-8. DOI: 10.1046/j.1365-2141.2003.04679.x. View

Chen R, Keating M, Gandhi V, Plunkett W . Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005; 106(7):2513-9. PMC: 1895272. DOI: 10.1182/blood-2005-04-1678. View

10.

Nabhan C, Patton D, Gordon L, Riley M, Kuzel T, Tallman M . A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2004; 45(11):2269-73. DOI: 10.1080/10428190412331286096. View

11.

MacFarlane M, Harper N, Snowden R, Dyer M, Barnett G, Pringle J . Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene. 2002; 21(44):6809-18. DOI: 10.1038/sj.onc.1205853. View

12.

Farahani M, Treweeke A, Toh C, Till K, Harris R, Cawley J . Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia. 2005; 19(4):524-30. DOI: 10.1038/sj.leu.2403631. View

13.

Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376(9747):1164-74. DOI: 10.1016/S0140-6736(10)61381-5. View

14.

Plumas J, Jacob M, Chaperot L, Molens J, Sotto J, Bensa J . Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood. 1998; 91(8):2875-85. View

15.

Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B . The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2010; 117(2):563-74. PMC: 3031480. DOI: 10.1182/blood-2010-05-284984. View

16.

Furman R, Forero-Torres A, Shustov A, Drachman J . A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009; 51(2):228-35. DOI: 10.3109/10428190903440946. View

17.

Morton L, Wang S, Devesa S, Hartge P, Weisenburger D, Linet M . Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2005; 107(1):265-76. PMC: 1895348. DOI: 10.1182/blood-2005-06-2508. View

18.

LeMaistre C, Saleh M, Kuzel T, Foss F, Platanias L, Schwartz G . Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998; 91(2):399-405. View

19.

Veldurthy A, Patz M, Hagist S, Pallasch C, Wendtner C, Hallek M . The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood. 2008; 112(4):1443-52. DOI: 10.1182/blood-2007-11-123984. View

20.

Ghia P, Granziero L, Chilosi M, Caligaris-Cappio F . Chronic B cell malignancies and bone marrow microenvironment. Semin Cancer Biol. 2002; 12(2):149-55. DOI: 10.1006/scbi.2001.0423. View